

**CLAIMS**

*Sub  
B:*

1. A method of selectively targeting a composition, selected from the group of: (a) particles, excluding liposomes, having a zeta potential in the range of about +25 mV to +100 mV in about 0.05 mM KCl solution at about pH 7.5; (b) molecules having an isoelectric point above 7.5; (c) liposomes containing cationic lipids in the range of about 25 mol% to 50 mol%; (d) magnetosomes with a cationic lipid layer having a zeta potential in the range of about +25 to +100 mV in about 0.05 mM KCl solution at about pH 7.5 and (e) oil-in-water emulsions or microemulsions containing cationic amphiphiles in the outer layer in the range of about 25 to 60 mol% or having a zeta potential in the range of about +25 mV to +100 mV in about 0.05 mM KCl solution at about pH 7.5.

2. The method of claim 1, wherein the activated vascular site is selected from the group consisting of: (a) sites of angiogenesis; (b) sites of inflammation; (c) sites of wound healing; and (d) the blood brain barrier.

3. An imaging composition for selective targeting to an activated vascular site, comprising an imaging agent and a carrier selected from the group consisting of: (a) particles, excluding liposomes, having a zeta potential in the range of about +25 mV to +100 mV in about 0.05 mM KCl solution at about pH 7.5; (b) molecules having an isoelectric point above 7.5; and (c) liposomes containing cationic lipids in the range of about 25 mol% to 50 mol%; (d) magnetosomes with a cationic lipid layer having a zeta potential in the range of about +25 to +100 mV in about 0.05 mM KCl solution at about pH 7.5 and (e) oil-in-water emulsions or microemulsions containing cationic amphiphiles in the outer layer in the range of about 25 to 60 mol% or having a zeta potential in the range of about +25 mV to +100 mV in about 0.05 mM KCl solution at about pH 7.5.

100-0550-8852-10060

4. The imaging composition of claim 3, wherein the imaging agent is selected from the group consisting of iron oxide particles, dyes, fluorescent dyes, NMR labels, scintigraphic labels, gold particles, PET labels, ultrasound contrast media, and CT contrast media.

5. A method of selectively targeting an imaging agent to a site of angiogenesis in an animal, comprising the steps of administering to the animal a composition according to claim 3 or 4, and allowing the composition to selectively accumulate to a diagnostically effective level in the vicinity of the site of angiogenesis.

6. The method of claim 5, wherein the composition is administered by a route selected from the group consisting of oral administration, intravenous administration, transdermal administration, subcutaneous administration, intraperitoneal administration, intratumoral administration, intraarterial administration, intramuscular administration, instillation and aerosol administration.

7. A therapeutic composition for selective targeting to an activated vascular site, comprising a therapeutically effective amount of an active ingredient and a carrier, the composition being selected from the group consisting of: (a) particles, excluding liposomes, having a zeta potential in the range of about +25 mV to +100 mV in about 0.05 mM KCl solution at about pH 7.5; (b) molecules having an isoelectric point above 7.5; (c) liposomes containing cationic lipids in the range of about 25 mol% to 50 mol%; (d) magnetosomes with a cationic lipid layer having a zeta potential in the range of about +25 mV to +100 mV in about 0.05 mM KCl solution at about pH 7.5; (e) oil-in-water emulsions or microemulsions containing cationic amphiphiles in the outer layer in the range of about 25 to 60 mol% or having a zeta potential in the range of about +25 to +100 mV in about 0.05 mM KCl solution at about pH 7.5.

8. The therapeutic composition of claim 7 wherein the active ingredient is selected from the group consisting of cytostatics and cytotoxic agents.

100-50-325241860

9. The therapeutic composition of claim 8, wherein the cytostatics and cytotoxic agents are selected from the group consisting of taxanes, inorganic complexes, mitose inhibitors, hormones, anthracyclines, antibodies, topoisomerase inhibitors, antiinflammatory agents, alkaloids, interleukins, cytokines, growth factors, proteins, peptides, and tetracyclines.

10. A method of selectively targeting a therapeutic composition to a site of angiogenesis in an animal comprising the step of administering to the animal a composition according to claim 7 or 8, and allowing the composition to selectively accumulate to a therapeutically effective level in the vicinity of the site of angiogenesis.

11. The method of claim 5 or 10, wherein the animal is a mammal.

12. The method of claim 10, wherein the composition is administered by a route selected from the group consisting of oral administration, intravenous administration, intramuscular administration, transdermal administration, subcutaneous administration, intraperitoneal administration, intratumoral administration, intraarterial administration, instillation and aerosol administration.

13. A method for enhancing the selective association of a composition at an activated vascular site, comprising the step of modifying the composition to have one or more of the characteristics selected from the group consisting of: (a) a zeta potential in the range of about +25 mV to +100 mV in about 0.05 mM KCl solution at about pH 7.5; and (b) an isoelectric point between above 7.5.

14. The method of claim 1, wherein the activated vascular site is indicative of an angiogenesis associated disease.

15. The method of claim 14, wherein the angiogenesis associated disease is selected from the group consisting of diabetic retinopathy, chronic inflammatory diseases, rheumatoid arthritis, dermatitis, psoriasis, stomach ulcers, hematogenous and solid tumors as well as metastases thereof.

*Sub  
B2*

16. The method of claim 1, wherein the composition has been modified to increase its zeta potential to a level of at least about +25 mV.

17. The method of claim 1, wherein the composition has been modified through a reaction with a cation forming reagent that increases the isoelectric point of the agent relative to the non-modified agent to a value above 7.5.

18. The method of claim 17, wherein the composition has been modified by reacting with a cation forming reagent selected from the group consisting of ethylene diamine, hexamethylenediamine, triethylene tetraamine, 4-dimethylamino butylamine, N, N-dimethylaminoethyl amine, dimethylamino benzaldehyde, polylysine, and chitosan.

19. The method of claim 17, wherein the composition comprises a peptide or a protein.

20. A therapeutic composition comprising an active ingredient that is therapeutically effective for the treatment of an angiogenesis associated disease, the composition having a zeta potential within a range of about +25 mV to +100 mV in about 0.05 mM KCl solution at about pH 7.5 or an isoelectric point above 7.5, the composition further being labeled or packaged with directions for the administration of the composition to treat an angiogenesis associated disease.

21. A therapeutic composition comprising an active ingredient that is therapeutically effective to inhibit inflammation, the composition having a zeta potential within a range of about +25 to +100 mV in about 0.05 mM KCl solution at about pH 7.5 or an isoelectric point above

1000  
999  
998  
997  
996  
995  
994  
993  
992  
991  
990  
989  
988  
987  
986  
985  
984  
983  
982  
981  
980  
979  
978  
977  
976  
975  
974  
973  
972  
971  
970  
969  
968  
967  
966  
965  
964  
963  
962  
961  
960  
959  
958  
957  
956  
955  
954  
953  
952  
951  
950  
949  
948  
947  
946  
945  
944  
943  
942  
941  
940  
939  
938  
937  
936  
935  
934  
933  
932  
931  
930  
929  
928  
927  
926  
925  
924  
923  
922  
921  
920  
919  
918  
917  
916  
915  
914  
913  
912  
911  
910  
909  
908  
907  
906  
905  
904  
903  
902  
901  
900  
899  
898  
897  
896  
895  
894  
893  
892  
891  
890  
889  
888  
887  
886  
885  
884  
883  
882  
881  
880  
879  
878  
877  
876  
875  
874  
873  
872  
871  
870  
869  
868  
867  
866  
865  
864  
863  
862  
861  
860  
859  
858  
857  
856  
855  
854  
853  
852  
851  
850  
849  
848  
847  
846  
845  
844  
843  
842  
841  
840  
839  
838  
837  
836  
835  
834  
833  
832  
831  
830  
829  
828  
827  
826  
825  
824  
823  
822  
821  
820  
819  
818  
817  
816  
815  
814  
813  
812  
811  
810  
809  
808  
807  
806  
805  
804  
803  
802  
801  
800  
799  
798  
797  
796  
795  
794  
793  
792  
791  
790  
789  
788  
787  
786  
785  
784  
783  
782  
781  
780  
779  
778  
777  
776  
775  
774  
773  
772  
771  
770  
769  
768  
767  
766  
765  
764  
763  
762  
761  
760  
759  
758  
757  
756  
755  
754  
753  
752  
751  
750  
749  
748  
747  
746  
745  
744  
743  
742  
741  
740  
739  
738  
737  
736  
735  
734  
733  
732  
731  
730  
729  
728  
727  
726  
725  
724  
723  
722  
721  
720  
719  
718  
717  
716  
715  
714  
713  
712  
711  
710  
709  
708  
707  
706  
705  
704  
703  
702  
701  
700  
699  
698  
697  
696  
695  
694  
693  
692  
691  
690  
689  
688  
687  
686  
685  
684  
683  
682  
681  
680  
679  
678  
677  
676  
675  
674  
673  
672  
671  
670  
669  
668  
667  
666  
665  
664  
663  
662  
661  
660  
659  
658  
657  
656  
655  
654  
653  
652  
651  
650  
649  
648  
647  
646  
645  
644  
643  
642  
641  
640  
639  
638  
637  
636  
635  
634  
633  
632  
631  
630  
629  
628  
627  
626  
625  
624  
623  
622  
621  
620  
619  
618  
617  
616  
615  
614  
613  
612  
611  
610  
609  
608  
607  
606  
605  
604  
603  
602  
601  
600  
599  
598  
597  
596  
595  
594  
593  
592  
591  
590  
589  
588  
587  
586  
585  
584  
583  
582  
581  
580  
579  
578  
577  
576  
575  
574  
573  
572  
571  
570  
569  
568  
567  
566  
565  
564  
563  
562  
561  
560  
559  
558  
557  
556  
555  
554  
553  
552  
551  
550  
549  
548  
547  
546  
545  
544  
543  
542  
541  
540  
539  
538  
537  
536  
535  
534  
533  
532  
531  
530  
529  
528  
527  
526  
525  
524  
523  
522  
521  
520  
519  
518  
517  
516  
515  
514  
513  
512  
511  
510  
509  
508  
507  
506  
505  
504  
503  
502  
501  
500  
499  
498  
497  
496  
495  
494  
493  
492  
491  
490  
489  
488  
487  
486  
485  
484  
483  
482  
481  
480  
479  
478  
477  
476  
475  
474  
473  
472  
471  
470  
469  
468  
467  
466  
465  
464  
463  
462  
461  
460  
459  
458  
457  
456  
455  
454  
453  
452  
451  
450  
449  
448  
447  
446  
445  
444  
443  
442  
441  
440  
439  
438  
437  
436  
435  
434  
433  
432  
431  
430  
429  
428  
427  
426  
425  
424  
423  
422  
421  
420  
419  
418  
417  
416  
415  
414  
413  
412  
411  
410  
409  
408  
407  
406  
405  
404  
403  
402  
401  
400  
399  
398  
397  
396  
395  
394  
393  
392  
391  
390  
389  
388  
387  
386  
385  
384  
383  
382  
381  
380  
379  
378  
377  
376  
375  
374  
373  
372  
371  
370  
369  
368  
367  
366  
365  
364  
363  
362  
361  
360  
359  
358  
357  
356  
355  
354  
353  
352  
351  
350  
349  
348  
347  
346  
345  
344  
343  
342  
341  
340  
339  
338  
337  
336  
335  
334  
333  
332  
331  
330  
329  
328  
327  
326  
325  
324  
323  
322  
321  
320  
319  
318  
317  
316  
315  
314  
313  
312  
311  
310  
309  
308  
307  
306  
305  
304  
303  
302  
301  
300  
299  
298  
297  
296  
295  
294  
293  
292  
291  
290  
289  
288  
287  
286  
285  
284  
283  
282  
281  
280  
279  
278  
277  
276  
275  
274  
273  
272  
271  
270  
269  
268  
267  
266  
265  
264  
263  
262  
261  
260  
259  
258  
257  
256  
255  
254  
253  
252  
251  
250  
249  
248  
247  
246  
245  
244  
243  
242  
241  
240  
239  
238  
237  
236  
235  
234  
233  
232  
231  
230  
229  
228  
227  
226  
225  
224  
223  
222  
221  
220  
219  
218  
217  
216  
215  
214  
213  
212  
211  
210  
209  
208  
207  
206  
205  
204  
203  
202  
201  
200  
199  
198  
197  
196  
195  
194  
193  
192  
191  
190  
189  
188  
187  
186  
185  
184  
183  
182  
181  
180  
179  
178  
177  
176  
175  
174  
173  
172  
171  
170  
169  
168  
167  
166  
165  
164  
163  
162  
161  
160  
159  
158  
157  
156  
155  
154  
153  
152  
151  
150  
149  
148  
147  
146  
145  
144  
143  
142  
141  
140  
139  
138  
137  
136  
135  
134  
133  
132  
131  
130  
129  
128  
127  
126  
125  
124  
123  
122  
121  
120  
119  
118  
117  
116  
115  
114  
113  
112  
111  
110  
109  
108  
107  
106  
105  
104  
103  
102  
101  
100  
99  
98  
97  
96  
95  
94  
93  
92  
91  
90  
89  
88  
87  
86  
85  
84  
83  
82  
81  
80  
79  
78  
77  
76  
75  
74  
73  
72  
71  
70  
69  
68  
67  
66  
65  
64  
63  
62  
61  
60  
59  
58  
57  
56  
55  
54  
53  
52  
51  
50  
49  
48  
47  
46  
45  
44  
43  
42  
41  
40  
39  
38  
37  
36  
35  
34  
33  
32  
31  
30  
29  
28  
27  
26  
25  
24  
23  
22  
21  
20  
19  
18  
17  
16  
15  
14  
13  
12  
11  
10  
9  
8  
7  
6  
5  
4  
3  
2  
1

7.5, the composition further being labeled or packaged with directions for the administration of the composition to inflammation.

22. A therapeutic composition comprising an active ingredient that is therapeutically effective to promote bone repair or wound healing, the composition having a zeta potential within a range of about +25 to +100 mV in about 0.05 mM KCl solution at about pH 7.5 or an isoelectric point above 7.5, the composition further being labeled or packaged with directions for the administration of the composition to promote bone repair or wound healing.

23. A diagnostic composition comprising an active ingredient that is diagnostically effective for the diagnosis or imaging of an angiogenesis associated disease, the composition having zeta potential within a range of about +25 to +100 mV in about 0.05 mM KCl solution at about pH 7.5 or an isoelectric point above 7.5, the composition further being labeled or packaged with directions for the administration of the composition to diagnose or image an angiogenesis associated disease.

24. The therapeutic composition of claim 7, wherein the active ingredient is selected from the group consisting of etherlipid, alkyllysolecithin, alkyllysophopholipid, lysolipid, alkylphospholipid.

25. The therapeutic composition of claim 24, wherein the etherlipid is selected from the group consisting of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, 1-O-Hexadecyl-2-O-methyl-sn-glycerol, Hexadecyl phosphocholine, Octadecylphosphocholine.

26. The method of claim 1, wherein the composition comprises particles having a zeta potential in the range of about +25 mV to +60 mV in about 0.05 mM KCl solution at about pH 7.5.

27. The method of claim 26, wherein the composition comprises particles having a zeta potential in the range of about +30 to +50 mV in about 0.05 mM KCl solution at about pH 7.5.

28. The imaging composition of claim 3, wherein the composition comprises particles having a zeta potential in the range of about +25 mV to +60 mV in about 0.05 mM KCl solution at about pH 7.5.

29. The composition of claim 28, wherein the composition comprises particles having a zeta potential in the range of about +30 to +50 mV in about 0.05 mM KCl solution at about pH 7.5.


30. The therapeutic composition of claim 7, wherein the composition comprises particles having a zeta potential in the range of about +25 mV to +60 mV in about 0.05 mM KCl solution at about pH 7.5.

31. The composition of claim 30, wherein the composition comprises particles having a zeta potential in the range of about +30 to +50 mV in about 0.05 mM KCl solution at about pH 7.5.

32. The method of claim 12, wherein the composition is modified to increase or decrease its zeta potential to fall within the range of about +25 mV to +60 mV in about 0.05 mM KCl solution at about pH 7.5.

33. A method for identifying an optimal range of zeta potential for a composition for targeting to a specific site comprising evaluating zeta potential for the composition, wherein the composition is associated with different amounts of a cationic component, and identifying an optimal range of zeta potential.

34. A method of modifying a composition to enhance its efficacy comprising the associating of cationic components with the composition to produce a composition having an optimal range of zeta potential.

A handwritten signature consisting of stylized initials and a surname, appearing to read "J. D. A. B." or similar.

047664-5002-0